Detailed information for compound 1489587
Basic information
Technical information
- TDR Targets ID: 1489587
- Name: (E)-N-[2-[(2,5-dimethylphenyl)amino]-2-oxoeth yl]-3-furan-2-yl-N-methylprop-2-enamide
- MW: 312.363 | Formula: C18H20N2O3
-
H donors: 1
H acceptors: 2
LogP: 2.54
Rotable bonds: 7
Rule of 5 violations (Lipinski): 1 - SMILES: O=C(Nc1cc(C)ccc1C)CN(C(=O)/C=C/c1ccco1)C
- InChi: 1S/C18H20N2O3/c1-13-6-7-14(2)16(11-13)19-17(21)12-20(3)18(22)9-8-15-5-4-10-23-15/h4-11H,12H2,1-3H3,(H,19,21)/b9-8+
- InChiKey: GVTCJSUGWHSPFS-CMDGGOBGSA-N
Network
Hover on a compound node to display the structore
Synonyms
- (E)-N-[2-[(2,5-dimethylphenyl)amino]-2-oxo-ethyl]-3-(2-furyl)-N-methyl-prop-2-enamide
- (E)-N-[2-[(2,5-dimethylphenyl)amino]-2-oxoethyl]-3-(2-furyl)-N-methylprop-2-enamide
- (E)-N-[2-[(2,5-dimethylphenyl)amino]-2-keto-ethyl]-3-(2-furyl)-N-methyl-acrylamide
- (E)-N-[2-[(2,5-dimethylphenyl)amino]-2-oxo-ethyl]-3-furan-2-yl-N-methyl-prop-2-enamide
- T5420302
- MLS000770761
- SMR000343906
- ZINC03555385
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | K(lysine) acetyltransferase 2A | Starlite/ChEMBL | No references |
| Rattus norvegicus | Thioredoxin reductase 1, cytoplasmic | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Toxoplasma gondii | apocytochrome b, putative | 0.0179 | 0.0831 | 0.3122 |
| Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.013 | 0.0524 | 0.0464 |
| Toxoplasma gondii | thioredoxin reductase | 0.0057 | 0.0063 | 0.0138 |
| Loa Loa (eye worm) | acetyltransferase | 0.0175 | 0.0806 | 0.5273 |
| Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.013 | 0.0524 | 0.0464 |
| Wolbachia endosymbiont of Brugia malayi | cytochrome b subunit of the bc complex | 0.046 | 0.2601 | 0.5 |
| Plasmodium vivax | glutathione reductase, putative | 0.0057 | 0.0063 | 0.0138 |
| Trypanosoma brucei | trypanothione reductase | 0.0057 | 0.0063 | 0.5 |
| Schistosoma mansoni | cytochrome b | 0.0281 | 0.1473 | 0.3714 |
| Plasmodium vivax | thioredoxin reductase, putative | 0.0057 | 0.0063 | 0.0138 |
| Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0145 | 0.0616 | 0.0556 |
| Giardia lamblia | Histone acetyltransferase GCN5 | 0.0047 | 0 | 0.5 |
| Echinococcus granulosus | histone acetyltransferase KAT2B | 0.017 | 0.0775 | 0.2907 |
| Schistosoma mansoni | cytochrome b | 0.046 | 0.2601 | 1 |
| Mycobacterium tuberculosis | Probable dehydrogenase | 0.013 | 0.0524 | 0.0464 |
| Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.013 | 0.0524 | 0.0464 |
| Loa Loa (eye worm) | cytochrome b | 0.0281 | 0.1473 | 1 |
| Echinococcus granulosus | thioredoxin glutathione reductase | 0.0057 | 0.0063 | 0.0138 |
| Mycobacterium tuberculosis | Probable oxidoreductase | 0.0145 | 0.0616 | 0.0556 |
| Toxoplasma gondii | cytochrome b | 0.046 | 0.2601 | 1 |
| Leishmania major | trypanothione reductase | 0.0057 | 0.0063 | 0.5 |
| Onchocerca volvulus | 0.1633 | 1 | 0.5 | |
| Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0051 | 0.0027 | 0.5 |
| Mycobacterium tuberculosis | Probable reductase | 0.013 | 0.0524 | 0.0464 |
| Trypanosoma cruzi | trypanothione reductase, putative | 0.0057 | 0.0063 | 0.5 |
| Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0145 | 0.0616 | 0.0556 |
| Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0145 | 0.0616 | 0.0097 |
| Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.013 | 0.0524 | 0.0464 |
| Plasmodium falciparum | thioredoxin reductase | 0.0057 | 0.0063 | 0.024 |
| Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0051 | 0.0027 | 0.5 |
| Mycobacterium tuberculosis | Probable ubiquinol-cytochrome C reductase QcrB (cytochrome B subunit) | 0.1633 | 1 | 1 |
| Echinococcus granulosus | cytochrome B | 0.046 | 0.2601 | 1 |
| Mycobacterium ulcerans | ubiquinol-cytochrome C reductase QcrB | 0.1633 | 1 | 0.5 |
| Plasmodium vivax | cytochrome b | 0.046 | 0.2601 | 1 |
| Plasmodium falciparum | cytochrome b | 0.046 | 0.2601 | 1 |
| Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0175 | 0.0806 | 1 |
| Entamoeba histolytica | acetyltransferase, GNAT family | 0.0047 | 0 | 0.5 |
| Plasmodium falciparum | glutathione reductase | 0.0057 | 0.0063 | 0.024 |
| Brugia malayi | cytochrome b | 0.0281 | 0.1473 | 1 |
| Brugia malayi | acetyltransferase, GNAT family protein | 0.0175 | 0.0806 | 0.5273 |
| Toxoplasma gondii | apocytochrome b, putative | 0.046 | 0.2601 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Potency (functional) | 0.1 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
| Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
| Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL1702119
Bibliographic References
No literature references available for this target.
If you have references for this compound, please enter them in a user comment (below) or Contact us.